Stuart Paynter
Director of Finance/CFO chez OXFORD BIOMEDICA PLC
Fortune : 47 449 $ au 31/03/2024
Profil
Stuart Paynter is currently the Chief Financial Officer & Director at Oxford Biomedica Plc, as well as a Director at Oxxon Therapeutics Ltd.
and a Member of the Institute of Chartered Accountants in England & Wales.
He previously worked as the Finance Director-European Region at STERIS Ltd.
from 2001 to 2007, Senior Director-Finance Business at Shire Pharmaceuticals Ltd.
from 2007 to 2016, and Head-Finance Business Partnering at De La Rue Plc from 2016 to 2021.
He received his undergraduate degree from Imperial College London.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
OXFORD BIOMEDICA PLC
0,02% | 20/09/2023 | 18 687 ( 0,02% ) | 47 449 $ | 31/03/2024 |
Postes actifs de Stuart Paynter
| Sociétés | Poste | Début |
|---|---|---|
| OXFORD BIOMEDICA PLC | Director of Finance/CFO | 29/08/2017 |
Institute of Chartered Accountants in England & Wales
 Institute of Chartered Accountants in England & Wales Miscellaneous Commercial ServicesCommercial Services The Institute of Chartered Accountants in England & Wales ensures that its members, students, and affiliates maintain the highest standards of professional competency and conduct to protect the public interest. The non-profit company is based in London, UK, and has subsidiaries in the United Kingdom. With over 150,000 members, the institute provides technical information, helplines, and communities to its members. | Corporate Officer/Principal | - |
Oxford Biomedica (UK) Ltd.
 Oxford Biomedica (UK) Ltd. BiotechnologyHealth Technology Part of Oxford Biomedica Plc, Oxford Biomedica (UK) Ltd. is a viral vector contract development and manufacturing organization (CDMO) based in Oxford, UK. Oxford Biomedica (UK has over 25 years of experience in the industry and is committed to enabling its clients to deliver life-changing therapies to patients worldwide. The British company offers innovative solutions to cell and gene therapy biotechnology and biopharma companies by working across key viral vector delivery systems including adeno-associated virus (AAV) and lentiviral delivery system. | Director/Board Member | - |
Oxxon Therapeutics Ltd.
 Oxxon Therapeutics Ltd. BiotechnologyHealth Technology Part of Oxford Biomedica Plc, Oxxon Therapeutics Ltd. is a biotechnology company. Oxxon Therapeutics Ltd. is based in Oxford, UK. Oxxon Therapeutics was acquired by Oxford Biomedica Plc on March 15, 2007 for $24.89 million. The British company was founded in 1998. | Director/Board Member | 29/08/2017 |
Anciens postes connus de Stuart Paynter
| Sociétés | Poste | Fin |
|---|---|---|
| DE LA RUE PLC | Corporate Officer/Principal | 01/07/2021 |
Shire Pharmaceuticals Ltd.
 Shire Pharmaceuticals Ltd. BiotechnologyHealth Technology Part of Takeda Pharmaceutical Co., Ltd., Shire Pharmaceuticals Ltd. is a patient-focused, British innovation-driven pharmaceutical company. The private company is based in London, UK. Takeda has a distinguished 240-year history and aspires to bring better health and a brighter future for people worldwide. Shire Pharmaceuticals was founded in 1986. The CEO is Flemming Ørnskov. | Director of Finance/CFO | 01/02/2016 |
STERIS Ltd.
 STERIS Ltd. Medical SpecialtiesHealth Technology STERIS Ltd. engages in the provision of infection prevention and other procedural products and services. It operates through the following segments: Healthcare Products, Healthcare Specialty Services, Life Sciences, and Applied Sterilization Technologies. The Healthcare Products segment offers infection prevention and procedural solutions for healthcare providers worldwide, including capital equipment, and related maintenance and installation services, as well as consumables. The Healthcare Specialty Services segment provides a range of specialty services for healthcare providers including hospital sterilization services, instrument and scope repairs, and linen management. The Life Sciences segment gives capital equipment and consumable products, and equipment maintenance and specialty services for pharmaceutical manufacturers and research facilities. The Applied Sterilization Technologies segment involves in contract sterilization and laboratory services for medical device and pharmaceutical Customers and others. The company was founded on October 9, 2014 and is headquartered in Chaddesden, the United Kingdom. | Corporate Officer/Principal | 01/07/2007 |
Formation de Stuart Paynter
| Imperial College London | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| DE LA RUE PLC | Commercial Services |
| OXFORD BIOMEDICA PLC | Health Technology |
| Entreprise privées | 5 |
|---|---|
STERIS Ltd.
STERIS Ltd. Medical SpecialtiesHealth Technology STERIS Ltd. engages in the provision of infection prevention and other procedural products and services. It operates through the following segments: Healthcare Products, Healthcare Specialty Services, Life Sciences, and Applied Sterilization Technologies. The Healthcare Products segment offers infection prevention and procedural solutions for healthcare providers worldwide, including capital equipment, and related maintenance and installation services, as well as consumables. The Healthcare Specialty Services segment provides a range of specialty services for healthcare providers including hospital sterilization services, instrument and scope repairs, and linen management. The Life Sciences segment gives capital equipment and consumable products, and equipment maintenance and specialty services for pharmaceutical manufacturers and research facilities. The Applied Sterilization Technologies segment involves in contract sterilization and laboratory services for medical device and pharmaceutical Customers and others. The company was founded on October 9, 2014 and is headquartered in Chaddesden, the United Kingdom. | Health Technology |
Institute of Chartered Accountants in England & Wales
Institute of Chartered Accountants in England & Wales Miscellaneous Commercial ServicesCommercial Services The Institute of Chartered Accountants in England & Wales ensures that its members, students, and affiliates maintain the highest standards of professional competency and conduct to protect the public interest. The non-profit company is based in London, UK, and has subsidiaries in the United Kingdom. With over 150,000 members, the institute provides technical information, helplines, and communities to its members. | Commercial Services |
Oxxon Therapeutics Ltd.
Oxxon Therapeutics Ltd. BiotechnologyHealth Technology Part of Oxford Biomedica Plc, Oxxon Therapeutics Ltd. is a biotechnology company. Oxxon Therapeutics Ltd. is based in Oxford, UK. Oxxon Therapeutics was acquired by Oxford Biomedica Plc on March 15, 2007 for $24.89 million. The British company was founded in 1998. | Health Technology |
Oxford Biomedica (UK) Ltd.
Oxford Biomedica (UK) Ltd. BiotechnologyHealth Technology Part of Oxford Biomedica Plc, Oxford Biomedica (UK) Ltd. is a viral vector contract development and manufacturing organization (CDMO) based in Oxford, UK. Oxford Biomedica (UK has over 25 years of experience in the industry and is committed to enabling its clients to deliver life-changing therapies to patients worldwide. The British company offers innovative solutions to cell and gene therapy biotechnology and biopharma companies by working across key viral vector delivery systems including adeno-associated virus (AAV) and lentiviral delivery system. | Health Technology |
Shire Pharmaceuticals Ltd.
Shire Pharmaceuticals Ltd. BiotechnologyHealth Technology Part of Takeda Pharmaceutical Co., Ltd., Shire Pharmaceuticals Ltd. is a patient-focused, British innovation-driven pharmaceutical company. The private company is based in London, UK. Takeda has a distinguished 240-year history and aspires to bring better health and a brighter future for people worldwide. Shire Pharmaceuticals was founded in 1986. The CEO is Flemming Ørnskov. | Health Technology |
